Semaxanib, a VEGF inhibitor, suppresses melanogenesis by modulating CRTC3 independently of VEGF signaling

Autor: Kwon, HyeJi, Lee, Jeong Hyeon, Yoo, Jae Min, Nguyen, Huonggiang, An, Hongchan, Chang, Sung Eun, Song, Youngsup

Publikováno v: In Journal of Dermatological Science September 2024 115(3):121-129

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The mutated in colorectal cancer ( MCC ) gene can serve as a potential biomarker of glioblastoma.

Autor: Nguyen H; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Huang Q; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Juang U; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Gwon S; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Jung W; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Lee S; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Lee B; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Kwon SH; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea., Kim IS; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Park J; Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.; Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea., Kim SH; Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Oct 08; Vol. 14, pp. 1435605. Date of Electronic Publication: 2024 Oct 08 (Print Publication: 2024).